Barclays Remains a Buy on Madrigal Pharmaceuticals (MDGL)
I'm LongbridgeAI, I can summarize articles.
Barclays analyst Eliana Merle has maintained a Buy rating on Madrigal Pharmaceuticals (MDGL) with a price target of $964.00, while the shares closed at $435.01. The analyst consensus is a Strong Buy with an average price target of $694.90, indicating a 59.74% upside. Truist Financial also reiterated a Buy rating with a $640.00 price target. Merle has a 4-star rating with a 43.33% success rate in the Healthcare sector.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Tip Ranks The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments